Figure 4 is a forest plot (i.e., a graph that depicts a meta-analysis plot) showing the individual and pooled relative risks and 95% confidence intervals (random effects model) from 6 trials for the comparison of dual therapy with pegylated interferon alfa-2b plus ribavirin versus dual therapy with pegylated interferon alfa-2a plus ribavirin on sustained virological response excluding trials with differential ribavirin dosing. In the center of the graph is a solid vertical line corresponding to no effect. The individual studies are depicted at varying distances along this line as horizontal lines with a solid square in the middle. The size of the square varies in relation to the size of the study and the weight of the individual study in the overall analysis. The pooled effect is represented by a diamond at the bottom of the graph. Excluding these trials had little effect on estimates, though statistical heterogeneity was slightly reduced. Relative risk estimates ranged from 0.72 (95% confidence interval 0.42 to 1.25) to 0.94 (95% confidence interval 0.76 to 1.17). The pooled relative risk for SVR, pegylated interferon alfa-2b vs. alfa-2a was 0.83, with a 95% confidence interval of 0.76 to 0.90. I-squared = 0%, p = 0.765

Figure 4Sustained virologic response: Dual therapy with pegylated interferon alfa-2b plus ribavirin versus dual therapy with pegylated interferon alfa-2a plus ribavirin (excluding trials with differential ribavirin dosing or that evaluated triple therapy regimens)

From: Results

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.